Cognition Therapeutics Inc. (NASDAQ: CGTX) presented plans for a Phase 3 program for its drug zervimesine in mild-to-moderate Alzheimer's disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE